HIMS THROUGH LABOR DAYThis is my speculative technical analysis of what I believe could unravel with $HIMS.
$45.00 has been crossed twice, and I believe this is where the line on the sand is drawn. A Strong close above this mark and we could see $47.40, $48.94, and then a gap fill to $50.00 which is a big psychological
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.745 EUR
121.75 M EUR
1.43 B EUR
202.68 M
About Hims & Hers Health, Inc.
Sector
Industry
CEO
Andrew Dudum
Website
Headquarters
San Francisco
Founded
2017
ISIN
US4330001060
FIGI
BBG00W6VZLW4
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Related stocks
HIMS OCT 2025HIMS — Price is holding above the 50–45 support and the rising trendline after repeated mid-range rejections. Supply/distribution remains inside the upper box (gap overhead). Bids show absorption in 50–45; 40 is the last institutional support before the weekly base at 25–20.
• Target up: 58–60 (gap
HIMS 1D: time to heal the trend?On the daily chart, Hims & Hers Health is testing a descending trendline, while MA50 and MA200 provide strong support from below. Buyers are clearly in control. The highlighted buy zone sits around $54.40, but the real signal comes only after a confirmed breakout and retest of the trendline.
Techn
Will Hims & Hers Health Sustain Its Bullish Growth Trajectory?Current Price: $52.54
Direction: LONG
Targets:
- T1 = $55.20
- T2 = $58.50
Stop Levels:
- S1 = $50.50
- S2 = $49.00
**Wisdom of Professional Traders:**
This analysis synthesizes insights from thousands of professional traders and market experts, leveraging collective intelligen
$HIMS growth slowdown ahead- NYSE:HIMS is quite overvalued. There's no moat to a business model.
- They got a good branding that's all. There are 10-15 other startups selling the same things under different umbrella.
- They even stole NYSE:NVO flagship weight loss drugs. These cheap alternatives will risk lives of peopl
$HIMS weekend analysis - 21st September, 2025Last week’s news-driven dip to the 48–49 range turned into a solid buying opportunity - the quick recovery shows it was more noise than substance. With the strong bounce, price looks set to retest the key 62.3 - 64.9 resistance zone, which could be the target for this week.
If we get a daily close
Hims long into supplyHims has decided to push the supply as we previously mentioned. We note a breakout of the OBV, which I have been tracking (momentum). As I previously stated, I was looking for a push to 60 again. Volatility has reset, and shorts are being squeezed. I would like to think that 51-ish is the new range,
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on HAM exchange Hims & Hers Health, Inc. Class A stocks are traded under the ticker 82W.
We've gathered analysts' opinions on Hims & Hers Health, Inc. Class A future price: according to them, 82W price has a max estimate of 71.96 EUR and a min estimate of 23.70 EUR. Watch 82W chart and read a more detailed Hims & Hers Health, Inc. Class A stock forecast: see what analysts think of Hims & Hers Health, Inc. Class A and suggest that you do with its stocks.
Yes, you can track Hims & Hers Health, Inc. Class A financials in yearly and quarterly reports right on TradingView.
Hims & Hers Health, Inc. Class A is going to release the next earnings report on Nov 3, 2025. Keep track of upcoming events with our Earnings Calendar.
82W earnings for the last quarter are 0.14 EUR per share, whereas the estimation was 0.13 EUR resulting in a 12.73% surprise. The estimated earnings for the next quarter are 0.08 EUR per share. See more details about Hims & Hers Health, Inc. Class A earnings.
Hims & Hers Health, Inc. Class A revenue for the last quarter amounts to 462.51 M EUR, despite the estimated figure of 468.31 M EUR. In the next quarter, revenue is expected to reach 493.71 M EUR.
82W net income for the last quarter is 36.08 M EUR, while the quarter before that showed 45.74 M EUR of net income which accounts for −21.12% change. Track more Hims & Hers Health, Inc. Class A financial stats to get the full picture.
No, 82W doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 15, 2025, the company has 1.64 K employees. See our rating of the largest employees — is Hims & Hers Health, Inc. Class A on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Hims & Hers Health, Inc. Class A EBITDA is 140.96 M EUR, and current EBITDA margin is 5.76%. See more stats in Hims & Hers Health, Inc. Class A financial statements.
Like other stocks, 82W shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hims & Hers Health, Inc. Class A stock right from TradingView charts — choose your broker and connect to your account.